Is This the Perfect Time to Buy Canopy Growth (TSX:WEED) Stock?

It could be a great time to take a contrarian position in legal marijuana leader Canopy Growth Corp (TSX:WEED)(NYSE:CGC).

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Investing isn’t just about being right; it’s also about being right at the perfect time. In the early 90s you could have predicted that the rising crop of internet startups were likely to create trillions of dollars in value over their lifetime. However, if you’d invested in these companies right away, you would have probably lost all your money in the dot-com crash of 2001. 

A similar pattern seems to have emerged in Canada’s legal marijuana sector. Savvy investors who bet on legalization early in 2015 and 2016 were rewarded with unbelievable gains when marijuana was officially legalized in 2018. However, the sector failed to live up to expectations in 2019, and valuations came crashing down. 

Industry leader Canopy Growth (TSX:WEED)(NYSE:CGC) probably lost the most. The company’s stock price plunged nearly 70% between April and November 2019. That’s over $12 billion in market capitalization wiped off in fewer than eight months. The company also lost its founder and chief executive officer, while the board initiated a painful restructuring process. 

Canopy wasn’t alone. Many of the company’s top rivals also lost billions in market value and senior staff, as Canadian investors reassessed the true economic impact of legalizing the drug for consumers. Some high-profile names folded, while others trade at a fraction of their former valuation. 

It may be fair to say that the overall sentiment for the legal cannabis sector is as pessimistic as ever, which could mean that it’s the perfect time for investors to take another look under the hood and make some contrarian bets. I believe that industry leader Canopy Growth is probably undervalued for the first time in years. Here’s why. 

Market consolidation

A market correction culls the herd and reduces competitive pressures for the top players. Now that some cannabis producers have gone out of business and plenty of smaller companies face bankruptcy, industry leaders like Canopy Growth can grab more market share and consolidate their position. 

The company already controls roughly one-third of the domestic market, which puts it in a favourable position to dominate foreign markets as well. 

Edibles

In 2019, Canada legalized several new categories of cannabis products beyond the traditional buds and rolls. Now, producers can market edible products such as brownies and beverages like marijuana-infused beer. This move could effectively double or triple the market for cannabis, according to my Fool colleague Ryan Vanzo. 

I believe these new categories should be easier to brand, market and consume, leading to margin expansion for the top players. Canopy already has several well-established brands like Tweed and Tokyo Smoke along with celebrity partnerships with Seth Rogan and Drake that give the company a competitive edge in this arena. 

Resources

Perhaps the best reason to be optimistic about Canopy’s prospects is its unparalleled economic resources. The company has $2.28 billion in cash and cash equivalents and $15 in per share book value, while the market price is $30 per share. It’s also backed by the resources and distribution network of its parent company, Constellation Brands.  

Those resources dramatically increase Canopy’s chances of survival as the market drags itself through this painful consolidation period. 

Bottom line

With its brands, cash, and attractive valuation, it may be the perfect time to add Canopy Growth stock to your long-term growth portfolio. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands. Fool contributor Vishesh Raisinghani has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »